MPB vs NBIX · P/E 15, $837.4M cap vs P/E 45, rev $2.36B
Mid Penn Bancorp (MPB) versus Neurocrine Biosciences Inc (NBIX) — a side-by-side from cached financials, not a winner call.
Mid Penn Bancorp (MPB) is a banks - regional company listed on US.
Neurocrine Biosciences Inc (NBIX) is a drug manufacturers - specialty & generic company listed on US.
MPB does not have a complete income-statement cache yet.
Latest reported NBIX revenue for 2024-12-31 was $2.36B. Net income was $341.3M. Revenue was up 24.8% from 2023-12-31 to 2024-12-31. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
MPB currently screens at market cap $837.4M and trailing P/E 15.0. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
Not investment advice. Open the MPB and NBIX stock pages for the full models.
Not investment advice.